Immuno-Biological Laboratories Co., Ltd. (TYO:4570)
1,510.00
+36.00 (2.44%)
Apr 17, 2026, 3:30 PM JST
TYO:4570 Revenue
Immuno-Biological Laboratories had revenue of 257.00M JPY in the quarter ending December 31, 2025, with 8.90% growth. This brings the company's revenue in the last twelve months to 1.03B, up 8.76% year-over-year. In the fiscal year ending March 31, 2025, Immuno-Biological Laboratories had annual revenue of 969.00M with 18.75% growth.
Revenue (ttm)
1.03B
Revenue Growth
+8.76%
P/S Ratio
13.64
Revenue / Employee
17.78M
Employees
58
Market Cap
14.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 969.00M | 153.00M | 18.75% |
| Mar 31, 2024 | 816.00M | 22.00M | 2.77% |
| Mar 31, 2023 | 794.00M | 147.00M | 22.72% |
| Mar 31, 2022 | 647.00M | 45.00M | 7.48% |
| Mar 31, 2021 | 602.00M | 26.00M | 4.51% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 7.06B |
| RaQualia Pharma | 3.98B |
| ReproCELL | 2.52B |
| OncoTherapy Science | 784.00M |
| CellSeed | 161.00M |
| Nano Holdings | 155.00M |
| Renascience | 107.00M |
| Kubota Pharmaceutical Holdings | 21.00M |